 |
BioCentury This WeekAuthor: BioCentury
BioCentury's streaming commentary on biotech industry trends, plus interviews with KOLs.For three decades, BioCentury has helped biopharma executives and investors make business-critical decisions and build larger networks with peers across the innovation ecosystem. Language: en-us Genres: Business, Life Sciences, Science Contact email: Get it Feed URL: Get it iTunes ID: Get it |
Listen Now...
Ep. 363 - New targets at AACR, biopharma deals, Kurma fund
Episode 653
Monday, 27 April, 2026
More than 175 new oncology targets surfaced at this year’s American Association for Cancer Research annual meeting in San Diego, with the focus on new ways to enhance the immune response against solid tumors and to make existing immunotherapies more effective. On the latest BioCentury This Week podcast, BioCentury’s analysts assess the new targets identified among the thousands of abstracts at AACR, as well as emerging pan-RAS inhibiting antibody-drug conjugates.The analysts also discuss Eli Lilly's latest deal — for a JAK-2 inhibitor from Ajax — and what the current pace of M&A and partnerships says about the state of biopharma dealmaking. This episode also features Kurma Partners’ new venture fund and the latest in BioCentury’s Emerging Company Profile series, spotlighting U.K.-based rheumatoid arthritis company Elevara Medicines. This episode of the BioCentury This Week podcast was brought to you by IQVIA Biotech.View full story: https://www.biocentury.com/article/659298#AACR #OncologyTargets #Immunotherapy #BiotechMA #ADC00:01 - Sponsor Message: IQVIA Biotech02:50 - AACR: New Targets11:08 - AACR: Pan-RAS Inhibitor ADCs15:35 - Biopharma Deals23:53 - Kurma's New Venture Fund27:28 - Emerging Company Profile: ElevaraTo submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text
